Showing 1981-1990 of 2150 results for "".
- EMA Accepts Drug Application for Regulatory Approval of Rhokiinsa (Rhopressa)https://modernod.com/news/ema-accepts-drug-application-for-regulatory-approval-of-rhokiinsa-rhopressa/2479802/Aerie Pharmaceuticals reported that the European Medicines Agency (EMA) has accepted for review the MAA for Rhokiinsa (netarsudil ophthalmic solution) 0.02%. Rhokiinsa is currently marketed as Rhopressa in the United States and is indicated for the reduction of elevated IOP in patients with open-
- The Vision Council Conducts Study on Contact Lens Subscription Serviceshttps://modernod.com/news/the-vision-council-conducts-study-on-contact-lens-subscription-services/2479830/The Vision Council’s market research team has developed an industry first look at the new and emerging contact lens subscription services. This study aims to examine the potential impact on the contact lens and optical retail industries. “We have recently seen several new contact lens subs
- Novartis: New Analysis of Phase 3 Brolucizumab Data Reinforces Superior Reduction of Retinal Fluidhttps://modernod.com/news/novartis-new-analysis-of-phase-3-brolucizumab-data-reinforces-superior-reduction-of-retinal-fluid/2479846/Novartis announced a new data analysis showing that retinal fluid was detected less often in patients treated with brolucizumab (RTH258) 6 mg versus aflibercept over four visits between weeks 36 to 48[1]. Retinal fluid is a key marker of disease activity in neovascular age-related macular degener
- Optos Launches Monaco Ultra-Widefield Retinal Imaging Systemhttps://modernod.com/news/optos-launches-monaco-ultra-widefield-retinal-imaging-system/2479855/Optos has launched Monaco, its latest ultra-widefield device to the European ophthalmic market. Monaco is the only ultra-widefield retinal imaging system with integrated Optical Coherence Tomography (OCT), according to Optos. It produces a 200° single-capture optomap image in less than hal
- IOT Launches New Corporate Brandinghttps://modernod.com/news/iot-launches-new-corporate-branding/2479870/Optical technology company IOT has announced a change in brand identity as part of an overall strategy to better communicate its culture, values, and approach to market. The new website and social media profiles are designed to help the company share optical knowledge as well as information abou
- Neurolens Appoints Thomas J. Chirillo as Chief Commercial Officerhttps://modernod.com/news/neurolens-appoints-thomas-j-chirillo-as-chief-commercial-officer/2479876/Neurolens announced the appointment of Thomas J. Chirillo as Chief Commercial Officer. An accomplished senior healthcare executive with deep experience in the eye care space, Mr. Chirillo brings almost 4 decades of sales and marketing experience to neurolens. “We’re thrilled to have someon
- Chinese Regulators Clear Takeda’s $62-Billion Takeover of Shirehttps://modernod.com/news/chinese-regulators-clear-takedas-62-billion-takeover-of-shire/2479882/Takeda said that China’s State Administration for Market Regulation has granted unconditional approval of its proposed $62-billion purchase of Shire. The Japanese drugmaker expects to complete the transaction in the first half of next year. China’s regulatory clearance “
- Devices to Expand Role of Surgery in Glaucoma Treatmenthttps://modernod.com/news/devices-to-expand-role-of-surgery-in-glaucoma-treatment/2479914/The glaucoma surgical device market is expected to grow at a rate of nearly 23 percent over the next 5 years, according to a Market Scope report. The market is expected to grow to nearly $1.7 billion by 2023, up from a small base of just under $634 million in 2018. Minimally invasive glauc
- REGENXBIO Reports Second Quarter 2018 Financial and Operating Results and Interim Data From Ongoing Clinical Trialshttps://modernod.com/news/regenxbio-reports-second-quarter-2018-financial-and-operating-results-and-interim-data-from-ongoing-clinical-trials/2479954/REGENXBIO Inc. announced financial results for the quarter ended June 30, 2018, and recent operational highlights including updates to interim data from its ongoing clinical trials. Financial Results Cash, cash equivalents, and marketable securities were $306.3 million as of June
- EyePoint Pharmaceuticals Appoints David Price as Chief Financial Officerhttps://modernod.com/news/eyepoint-pharmaceuticals-appoints-david-price-as-chief-financial-officer/2479969/EyePoint Pharmaceuticals announced the appointment of David Price as Chief Financial Officer, effective immediately. In this role, Mr. Price will oversee and lead the company’s financial and capital markets activities. Mr. Price brings to EyePoint more than 25 years of financial experience